Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial Officer
February 14, 2024 at 05:01 pm EST
Share
On February 9, 2024, Bio-Rad Laboratories, Inc.?s board of directors appointed Norman Schwartz, the Company?s President and Chief Executive Officer and the Chairman of the Board, as the Company?s principal financial officer until a permanent replacement for Ilan Daskal has been appointed.
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows:
- manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems;
- manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets;
- other (0.1%): in particular, manufacturing of analytical instruments.
At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore.
Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
BIO-RAD LABORATORIES, INC. 
